A POPULATION PHARMACOKINETIC MODEL OF ADALIMUMAB IN A COHORT OF PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWOL DISEASE: A PRELIMINARY ANALYSIS (submitted in 2019)